|23rd November 2020||Srinivas Akkaraju||500,000||Grant/award etc.||$10.00||$5,000,000.00|
|18th November 2020||David W Gryska||50,000||Open or private sale||$2.39||$119,500.00|
|18th November 2020||David W Gryska||60,000||Exercise of derivative||$1.64||$98,400.00|
|17th November 2020||David W Gryska||100,000||Open or private sale||$2.40||$240,000.00|
|9th November 2020||Alpna Seth||1,358||Open or private sale||$305.74||$415,194.92|
|9th November 2020||Alpna Seth||3,125||Exercise of derivative||$125.05||$390,781.25|
|9th November 2020||Alpna Seth||3,665||Open or private sale||$306.95||$1,124,971.75|
|9th November 2020||Alpna Seth||1,898||Exercise of derivative||$179.84||$341,336.32|
|5th November 2020||David W Gryska||4,500||Open or private sale||$180.60||$812,699.10|
|4th November 2020||Charles R Romp||1,590||Exercise of derivative||$34.20||$54,378.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Seattle Genetics, Inc. is a biotechnology company. It engages in the development and commercialization of antibody-based therapies for the treatment of cancer. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.